Training Program in Stem Cell Research at UCSF

Refine your search

Disease Focus

Institution

Grant Type

Grant Award Details

Training Program in Stem Cell Research at UCSF

Grant Type:

Research Training II

Grant Number:

TG2-01153

Project Objective:

To provide comprehensive stem cell training and support for 6 graduate students, 6 postdoctoral (Ph.D.) fellows, and 4 clinician-scientists.

Investigator:

Name:

Susan Fisher

Institution:

University of California, San Francisco

Type:

Award Value:

$7,814,027

Status:

Closed

Progress Reports

Reporting Period:

Year 4

View Report

This training grant is a very valuable asset to a broad range of UCSF programs. The resources that are made available to our Scholars enrich graduate education and the training experiences of the postdoctoral and clinical fellows that are supported under this mechanism. A description of the various components of our training program follows. The process of securing a CIRM-sponsored fellowship at UCSF is very competitive. We work extremely hard to make sure that open positions are widely advertised to our various constituencies. These include the many graduate groups, the departments with which they are affiliated and the clinical training programs. Announcements are made through several routes including LISTSERVES and in person at seminars, journal clubs, workshops and retreats. We know that a strong, fair and open application process is key to recruiting truly outstanding trainees. One aspect is making sure the applicants have sufficient time to prepare outstanding proposals. Therefore, the announcement of vacant positions is made at least four weeks before the application due date. The proposal has several components, including a three-page research plan, a mentor training plan/letter and biographical sketches from the applicant and his/her Principal Investigator. We ask for two additional reference letters from individuals who know the prospective Fellow well, and can make detailed comments about their past accomplishments and future potential. A committee consisting of UCSF scientists, who broadly represent the major stem cell research pipelines at this university, reviews the applications. Two individuals provide written critiques and scorers for each application. Thus, we use objective criteria to choose the Scholars. Our trainees take advantage of the numerous and varied stem cell-related activities that are sponsored by this program and available at UCSF. This year we started a new activity, CIRM Scholar Lunches. These meetings are designed to bring the pre-doctoral students, postdoctoral fellows and clinical fellows that this training grant supports together with the leadership of the program. We allot time for general discussions and to cover special topics. During the past year the latter included ethical issues in stem cell biology, careers in the biotechnology sector, obtaining venture capital for start-ups, licensing and patenting. The Scholars also attend local, national and international meetings. The CIRM annual meeting is a popular event that brings them together with trainees and their mentors from other universities. This is a valuable opportunity for scientific interchange and networking. Many also attend the annual meeting of the International Society for Stem Cell Research, which is an exciting opportunity to meet the thought leaders in many branches of stem cell science. The other meetings they attend are usually more specialized, focusing on their particular areas of research. At UCSF they take advantage of many retreats that are held annually. Examples include those that are sponsored by the Biomedical Sciences Program, The Developmental and Stem Cell Biology Program and the Program in Biomedical Sciences. They also attend lectures that are part of the 11 regular seminar series at this university. Some are entirely focused on topics in stem cell biology and others include speakers who work in the field. The Scholars also participate in Journal Clubs, where exciting new publications are discussed and in Workshops, where they have an opportunity to present work in progress and receive feedback from the students, fellows and faculty who attend. They also take formal courses or audit these offerings. Some are specially designed for stem cell trainees such as Developmental and Stem Cell Biology, which integrates fundamental concepts in these fields. They also take the one-week Stem Cell Biology course that is offered by the UCSF CIRM Shared Lab and Teaching Facility, which has both a lecture in the laboratory component. They also participate in a course that addresses ethical issues in stem cell biology research. On an individual basis they attend more specialized courses that are specially tailored to their fields of study. Program administration is directed by the Principal Investigator and the Co-Principal Investigator, Dr. Robert Blelloch, a physician and scientist. A strong oversight committee, consisting of prominent UCSF stem cell scientists, helps manage this important resource. A talented staff handles financial and other administrative aspects of the training grant. In summary, we have designed a training program with maximal benefits to our CIRM Scholars. As a group, they have gone on to many types of careers in the stem cell sciences. They have taken jobs in the biotechnology sector and in academia. We think that their training experiences at UCSF have given them a very strong foundation on which to build successful careers.

Reporting Period:

Year 5

View Report

The UCSF CIRM training grant is a critical component of graduate and postgraduate education at this institution. This unique resource enables the training of individuals who will go on to basic research in a laboratory setting. The diverse nature of our faculty mentors assures that equal importance is given to educating trainees who are interested in translating research findings into clinical therapies. As a group, our past and current trainees include top tier young investigators in the field of regenerative medicine. Our CIRM Scholars enter the program following a rigorous selection process. Open slots are widely advertised 4-6 weeks prior to the due date. The mechanisms include the listservs of our graduate programs, clinical chairs and The Eli & Edythe Broad Center for Regeneration Medicine and Stem Cell Research at UCSF. Current mentors and trainees are ambassadors for our program. The application process is designed to be rigorous and fair. Prospective trainees write a three-page research plan, which is accompanied by the mentor’s individual training program and three letters of reference. This material, and the biographical sketches of the student and faculty member, provide a very complete picture of the applicant’s past accomplishments, planned experiments and future potential, information that is key to the integrity of the selection process. Reviews are conducted by an experienced faculty committee representing the broad range of stem cell-related activities at this institution. Formal written critiques are prepared and numerical scores given, which enable ranking. Many applicants apply. As a result, our trainees are from the top echelon. As to Program activities, UCSF offers an outstanding environment for stem cell and regenerative medicine research, in general, and our CIRM trainees in particular. This includes a dozen formal seminar series. They also attend the Stem Cell Journal Club, a discussion of high profile recent papers, and the Stem Cell Workshop, where they present work in progress. Every major program at UCSF holds an annual retreat. Our CIRM Scholars are required to attend one of these events. Finally, they use their travel allowances to attend national and international meetings on various topics in the fields of stem cell and developmental biology, as well as more clinically oriented symposia as related to regenerative medicine therapies. This year our Scholars had the added benefit of attending the Third Annual Tri-Institutional Stem Cell Retreat that included speakers from UCSF, UCLA and USC. We also sponsor lunch-time get-togethers for all trainees, which are led by the Program Director. This venue is a valuable forum for research presentations and discussions, for example, ethical issues and career counseling. The courses that our trainees take depend on their educational level. Graduate students are enrolled in formal instruction; the exact components of the curriculum depend on the program, most commonly Biological Sciences, Biomedical Sciences or Developmental and Stem Cell Biology. As their research interests mature, they sometimes seek additional coursework, for example, in computer programming. The postdoctoral fellows and physician-scientists tend to have completed their coursework and focus on research. However, (along with the graduate students) they participate in the program activities. They are required to take classroom instruction regarding the Responsible Conduct of Research and Ethical Issues as Related to Stem Cell Research. In addition, several elect to take our CIRM Shared Laboratory Training Course, and attend lectures in the graduate courses that are relevant to their research. Our CIRM training grant benefits from having a very capable administrative head who works with additional staff in the office of The Eli & Edythe Broad Center for Regeneration Medicine and Stem Cell Research at UCSF. The chief administrator assists the Program Director in all aspects of the day-to-day operations of the training grant. He monitors upcoming openings in the program and works with the Principal Investigator to strategize efforts to effectively and efficiently select new trainees. He also processes all appointments, renewals and terminations for the CIRM Fellows. He serves as a liaison between trainees, CIRM and institutional offices. Although not his primary duty, he helps the Program Director manage the financial aspects of this grant, which are handled by the office of The Broad Center. Our governance structure includes an Oversight Committee with members who are leaders in stem cell research and regenerative medicine. In summary, our training program has been very successful. We are producing the next generation of leaders in stem cell/developmental biology and the translational and therapeutic applications that are emerging from these fields. Thus, our CIRM scholars are fueling the pipeline that will deliver stem cell-based therapies to the citizens of California.

Reporting Period:

Year 6

View Report

All aspects of the UCSF CIRM Training grant were extremely successful. Below we describe elements of the program that contributed to its success. They included strategies used for recruiting scholars, activities that the vibrant UCSF community had to offer, courses the scholars could take and how the program was administered. By combining all these elements, UCSF offered a unique environment that greatly benefited our scholars. As to recruitment, we devised very effective mechanisms for reaching the entire UCSF community of potential trainees. These included graduate students, postdoctoral and clinical fellows. In the end, it was clear that one of the most important tools we had was time. Making sure that we announced open slots as soon in the cycle as possible assured that the information spread widely. We wanted to fill the slots quickly, but we also wanted to give as many people as possible the chance to put together competitive applications. Open slots were announced via the email lists of the relevant graduate and clinical programs. As to selection, trainees were chosen on the basis of a written application. The application had several parts. The first was a 3-page summary of the proposed research project. The length enabled a clear outline of the research strategy without putting an onerous burden on the applicant. The second was the mentor’s training plan. This portion was designed to illuminate the mentor-trainee relationship and the unique opportunities that were being offered. This letter also served as one of three recommendations that were required. We also asked that Biographical Sketches be submitted by the applicant and mentor. The applications were ranked in a face-to-face meeting of the selection committee, which was composed of seasoned reviewers who have evaluated applications for all the major US agencies that fund research in the biomedical sciences. As a group, their collective expertise covered most of the scientific areas in which applications were submitted. As the training grant wound down, the Scholars attended program activities sponsored by the Graduate Programs and Centers with which they were most closely aligned. This included the Biomedical Sciences Seminar Series. They also attended the Stem Cell Seminar Series as well as the Program in Biological Sciences offerings. They participated in Workshops and Journal Clubs that were sponsored by these programs. The retreats they attended included those held by the Biomedical Sciences Graduate Program, the Developmental and Stem Cell Biology Graduate Program, The Diabetes Center and the Cardiovascular Research Institute. They also presented the results of their work at national and international meetings on various aspects of stem cell biology, ranging from basic science to clinical applications. With regard to courses, the Scholars were invited to participate in a 1-week course that the UCSF CIRM Shared Laboratory and Teaching Facility offered. They also took a classroom course in ethics and the responsible conduct of research. The course covered several timely topics: scientific misconduct (plagiarism, falsification, and fabrication of data), scientific record keeping and data management, animals in research (animal rights and welfare), human subjects in research, publication and responsible authorship along with peer review practices, conflicts of interest, mentoring and being mentored. Other coursework included the core course in Developmental and Stem Cell Biology, Introduction to Human Biology and Medicine, and Tissue and Organ Biology. With regard to administration, the Program Coordinator handled all aspects of the trainee selection process. This included taking primary responsibility for keeping track of the trainees and their terms of appointment. The Coordinator was also in charge of advertising open positions, organizing receipt of the applications, notifying the review committee and setting the meeting date. Two reviewers were assigned per application. Written comments were solicited via a review form and scoring sheet. After a face-to-face ranking meeting, the Coordinator communicated the results via e-mail to the applicants. Other administrative duties included handling all routine communications with our trainees, coordinating the submission of the annual progress reports, preparing the appointment forms, assembling the final report and collecting the various types of additional paperwork that were relevant to each application. We also had strong faculty leadership. It was a pleasure to administer this program. The training grant benefited many scholars at different stages of the educational process. Administering the grant meant, in real terms, that the staff and faculty who were involved got to know the trainees. As a group we are proud of their accomplishments and the tangible benefits we could offer through the training grant, which enabled them to come closer to reaching their career goals.

Grant Application Details

Application Title:

Training Program in Stem Cell Research

Public Abstract:

Our goal is to continue the Type I CIRM-funded Comprehensive Training Program that was established at this institution nearly 3 years ago. Specifically, we want to support 6 graduate students, 6 postdoctoral (Ph.D.) fellows, and 4 clinician-scientists (M.D. and or Ph.D.). We provide a unique training environment for students at all levels who are pursuing careers in regenerative medicine. Specifically, our institution offers a world-class research training experience in the context of an equally prestigious medical school and clinical enterprise. We are also noted for our faculty, a diverse and talented group of individuals—1,500 full-time members who are renowned for their dedication to the training process. Additionally, this institution has a long history of supporting human embryonic stem cell research within a framework of the highest ethical standards of conduct. In this productive research environment, our regenerative medicine institute fosters work toward regenerative medicine therapies. The regenerative medicine institute has 7 pipelines that are designed to promote the development of cell-based therapies for repair/regeneration of cardiovascular, neural, pancreas and liver, hematopoietic, musculoskeletal, epithelial, and reproductive tissues. Each pipeline integrates the research of numerous investigators who are working together to translate basic research discoveries into clinically viable therapies. The pipelines are supported by programs that cut across several disciplines, including Human Embryonic Stem Cells, Cancer, Immunology, Genetics, and Bioengineering. Regenerative medicine institute research is supported by key technology core facilities. Additionally, we were awarded a grant to build and run a CIRM Shared Laboratory and Teaching Facility that will be an important resource for our trainees and a CIRM Major Facilities Award that will allow consolidation and expansion of stem cell-related activities in a new building. With regard to campus-wide events, the regenerative medicine institute sponsors many well-attended series, including regularly scheduled seminars, journal clubs, a young-faculty forum, and an annual retreat. These events take place against a backdrop of stimulating activities with similar formats in other programs that cover cutting-edge research developments in the U.S. and around the world. In this context, CIRM trainees at this university will have several different types of learning experiences that include formal courses in stem cell biology and related topics such as human development and cell biology. Ethical issues will be addressed in a course that is solely devoted to this topic. Trainees will also do research with world-class mentors who focus on transforming basic research discoveries into clinical applications. Thus, this university provides an exceptional and exciting environment for trainees who will be the next generation of leaders in the field of regenerative medicine.

Statement of Benefit to California:

We envision that the citizens of the state of California will benefit in many ways from continuing this institution’s Comprehensive Training Program for graduate students, postdoctoral fellows (Ph.D.), and clinician-scientists (M.D. and/or Ph.D.). Collectively, the basic research, translational strategies, and clinical therapies that will emerge from the work of this university’s California Institute for Regenerative Medicine (CIRM)-funded trainees will be an important stimulus to the state economy, particularly the biotechnology sector and associated medical enterprises. Additionally, specific groups of individuals will directly benefit from work that is focused on cell-based therapies for repairing tissues and organs whose damage leads to common medical conditions, such as diabetes, cardiovascular disease, Parkinson’s disease, paralysis and/or immune dysfunction. On the way to achieving the CIRM’s ultimate goals in terms of novel regenerative therapies for patients, we envision that numerous other benefits will emerge. For example, human embryonic stem cell (hESC) systems are powerful tools for unraveling the molecular bases of human development, which remain largely a black box. A fundamental lack of understanding regarding the mechanisms that give rise to the hundreds of cell types that form tissues and organs makes it extremely difficult to discern why these processes sometimes go awry, leading to birth defects and/or setting the stage for many diseases. Additionally, it is likely that novel therapies for other medical conditions will emerge. In this regard, some forms of cancer are now thought to be associated with the proliferation of stem cells that carry mutations in genes that promote their self-renewal rather than differentiation and integration into the compartment that they normally occupy. Other important applications include drug development. For example, hESCs and their differentiated progeny could be used to screen lead compounds for efficacy, safety and/or toxicity. Where will the workforce come from that will enable this revolution in how the medical establishment approaches patient care? Given the fact that hESCs were first described just 10 years ago, this is a very young field that must be rapidly populated with scientists and clinicians who are specially trained in all aspects of regenerative medicine, a new specialty. This necessity makes the funding of CIRM-sponsored training programs especially critical for institutions such as ours that have the ability to make important research discoveries and translate them into clinical therapies. In this regard, our university has a long and distinguished history of training leaders in science and/or medicine who easily traverse the boundaries between academia and industry. Our past successes strongly suggest that our CIRM-funded training programs will be equally successful. Accordingly, we expect that our trainees will become leaders in the field.

Publications

Nature (2014) Cell-autonomous correction of ring chromosomes in human induced pluripotent stem cells. (PubMed: 24413397)
Nat Cell Biol (2014) The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. (PubMed: 24561622)
Nature (2014) Mouse liver repopulation with hepatocytes generated from human fibroblasts. (PubMed: 24572354)
Proc Natl Acad Sci U S A (2014) Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal. (PubMed: 24711398)
Elife (2014) Distinct and separable roles for EZH2 in neurogenic astroglia. (PubMed: 24867641)
G3 (Bethesda) (2014) Enhancer-trap Flippase Lines for Clonal Analysis in the Drosophila Ovary. (PubMed: 25024257)
Nature (2014) Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. (PubMed: 25079315)
Cell Rep (2014) Control of Outer Radial Glial Stem Cell Mitosis in the Human Brain. (PubMed: 25088420)
Nat Biotechnol (2014) Low-coverage single-cell mRNA sequencing reveals cellular heterogeneity and activated signaling pathways in developing cerebral cortex. (PubMed: 25086649)
Nature (2014) Radial glia require PDGFD-PDGFRbeta signalling in human but not mouse neocortex. (PubMed: 25391964)
J Immunol (2014) Fetal Intervention Increases Maternal T Cell Awareness of the Foreign Conceptus and Can Lead to Immune-Mediated Fetal Demise. (PubMed: 24415782)
Semin Reprod Med (2013) Human trophoblast progenitors: where do they reside? (PubMed: 23329637)
Methods Mol Biol (2013) Directed differentiation of human pluripotent stem cells along the pancreatic endocrine lineage. (PubMed: 23546752)
Nat Commun (2013) Mitotic spindle orientation predicts outer radial glial cell generation in human neocortex. (PubMed: 23575669)
Cell Stem Cell (2013) Integration of Genome-wide Approaches Identifies lncRNAs of Adult Neural Stem Cells and Their Progeny In Vivo. (PubMed: 23583100)
Blood (2013) Direct and indirect antigen presentation lead to deletion of donor-specific T cells after in utero hematopoietic cell transplantation in mice. (PubMed: 23610372)
Cell Rep (2013) Bivalent Chromatin Marks Developmental Regulatory Genes in the Mouse Embryonic Germline In Vivo. (PubMed: 23727241)
Nature (2013) Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. (PubMed: 23812591)
Development (2013) A dynamic population of stromal cells contributes to the follicle stem cell niche in the Drosophila ovary. (PubMed: 24131631)
Dev Biol (2013) Cerebellar Cortical Lamination and Foliation Require Cyclin A2. (PubMed: 24184637)
J Pediatr Surg (2012) Alterations in maternal-fetal cellular trafficking after fetal surgery. (PubMed: 22703775)
J Cell Biol (2012) Nodal signaling regulates endodermal cell motility and actin dynamics via Rac1 and Prex1. (PubMed: 22945937)
PLoS One (2012) The bHLH Repressor Deadpan Regulates the Self-renewal and Specification of Drosophila Larval Neural Stem Cells Independently of Notch. (PubMed: 23056424)
Clin Perinatol (2012) In utero hematopoietic cell transplantation for the treatment of congenital anomalies. (PubMed: 22682381)
Chimerism (2012) Maternal microchimerism in patients with biliary atresia: Implications for allograft tolerance. (PubMed: 22772071)

California's Stem Cell Agency

California Institute for Regenerative Medicine

Grant Award Details

Progress Reports

View Report

View Report

View Report

Grant Application Details

Publications

Pages

aa Multiple Diseases (Centers & Resoures)
Aging
Arthritis
Blood Disorders
-Alpha Thalassemia Major
-Anemia
-Beta Thalassemia
-Bone Marrow Transplant and Viral Infection
-Hemophilia A
-Hyper IgM Syndrome
-IPEX Syndrome
-Leukocyte Adhesion Deficiency
-Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)
-Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
-Severe Combined Immunodeficiency, X-linked (X-SCID)
-Sickle Cell Disease
-X-linked Chronic Granulomatous Disease
Bone or Cartilage Disease
-Intervertebral disc degeneration
-Osteoarthritis
-Osteonecrosis
Cancer
-Blood Cancer
--Acute Myeloid Leukemia
--B cell cancers
--HIV-related Lymphoma
--Leukemia
--Leukemia, Acute Myeloid (AML)
--Multiple Myeloma
-Solid Tumors
--Brain Cancer
--Breast Cancer
--Colon Cancer
--Lung Cancer
--Melanoma
--Ovarian Cancer
--Pancreatic Cancer
--Prostate Cancer
--Sarcoma
--Skin cancer
Developmental Disorders
Fertility
Genetic Disorder
Hearing Loss
Heart Disease
-Heart disease associated with Duchenne muscular dystrophy
-Heart failure
-Pulmonary Hypertension
Immune Disease
-Thymic Disorder, 22q11 Deletion/DiGeorge
Incontinence
Infectious Disease
-COVID-19
-HIV/AIDS
-Zika virus
Kidney Disease
-Kidney Failure
Metabolic Disorders
-Cystinosis
-Danon Disease
-Diabetes
--Diabetic Wounds
--Type 1 diabetes
-Intestinal Disease
-Liver Disease
Multiple Indications (Alpha Clinics)
Neurological Disorders
-Alzheimer's Disease
-Amyotrophic Lateral Sclerosis
-Autism
-Brain Injury, hypoxic, ischemic
-Canavan Disease
-Dementia
-Epilepsy
-Huntington's Disease
-Multiple Sclerosis
-Neuropathy
-Parkinson's Disease
-Rett's Syndrome
-Spina Bifida
-Spinal Cord Injury
-Spinal Muscular Atrophy
-Stroke
-Traumatic Brain Injury
Other
Pediatrics
Respiratory Disorders
-Cystic Fibrosis
-Lung Disease, Fibrosis
Skeletal/Smooth Muscle disorders
-Bladder or Urinary Tract Disorder
-Muscular Dystrophy
Skin Disease
-Epidermolysis Bullosa
Toxicity
Trauma
Vascular Disease
Vision Loss
-Age-related macular degeneration
-Corneal Damage
-Retinitis Pigmentosa

Ali Nsair
Alliance Forum Foundation
Almac Diagnostics, Inc.
American Association of Blood Banks
Angiocrine Bioscience, Inc.
Ankasa Regenerative Therapeutics
Aspen Neuroscience
Benjamin D. Yu
Berkeley City College
Biocom Institute
BioTime, Inc.
Blood Cell Development and Disease Murdoch Childrens Research Institute The Royal Children's Hospital
Bluebird Bio
Brain Mapping Foundation
Brain Neurotherapy Bio
BrainStorm Cell Therapeutics
Buck Institute for Age Research
Cal Poly Pomona
Cal State Univ, Channel Island
Cal State Univ, Fullerton
Cal State Univ, Long Beach
Cal State Univ, Northridge
Cal State Univ, Sacramento
Cal State Univ, San Bernadino
Cal State Univ, San Marcos
Caladrius Biosciences
Calibr
California Institute of Technology
California Polytechnic State University, San Luis Obispo
Calimmune, Inc.
Capricor, Inc
Cedars-Sinai Medical Center
Cellerant Therapeutics, Inc.
Cellular Biomedicine Group, Inc.
Cellular Dynamics International
Celularity Inc
Centre National de la Recherche Scientifique
Chapman University
Charité Universitätsmedizin
Children's Hospital of Los Angeles
Children's Hospital of Oakland Research Institute
Children's Hospital of Orange County
Children's Neurobiological Solutions (CNS) Foundation
City College Of San Francisco
City of Hope, Beckman Research Institute
Escape Therapeutics, Inc
ExCellThera Inc.
Fate Therapeutics, Inc.
Fluidigm Corporation
Forty Seven Inc.
Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik
Fraunhofer-Institute for Cell Therapy and Immunology
FUJIFILM Cellular Dynamics
Gamma Medica-Ideas, Inc.
Geron Corporation
Gladstone Institutes, J. David
GMR Epigenetics
Gordon Research Conferences
HHMI/Boston Children's Hospital
Hospital Universitario Reina Sofia
Howard Florey Institute
Humacyte, Inc.
Human BioMolecular Research Institute
Human Organ Project
Humboldt State University
ImmunoCellular Therapeutics
International Alliance for Biological Standardization
International Society for Experimental Hematology
International Society for Stem Cell Research
International Symposium on Neural Regeneration, Inc.
iPierian, Inc.
IQVIA, Inc.
Jackson Labs
jCyte, Inc
JDRF International
Keio University
Keystone Symposia on Molecular and Cellular Biology
La Jolla Institute for Allergy and Immunology
Lineage Cell Therapeutics Inc.
Loma Linda University
Ludwig Institute for Cancer Research
MAX BioPharma, Inc.
Max-Planck Institute, Goettingen
Medeor Therapeutics, Inc.
Midwinter Conference of Immunologists
Mohammad Pashmforoush
Monash University
Mosaic Event Management, Inc.
National Cancer Institute
National Institutes of Health
Neurona Therapeutics
Nohla Therapeutics Inc
Numerate, Inc.
OCTANe Foundation for Innovation
Ocular Research Symposia Foundation, Inc.
OncoMed Pharmaceuticals, Inc.
Orchard Therapeutics plc
Palo Alto Veterans Institute for Research
Parkinson's Institute
Pasadena City College
Pathways to Stem Cell Science
Poseida Therapeutics, Inc.
Research for Cure
Reza Ardehali
Rocket Pharmaceuticals, Inc.
Rumi Scientific CA
RUNX1 Research Program
Salk Institute for Biological Studies
Samumed, LLC
San Diego State University Foundation
San Francisco State University
San Jose State University
SanBio, Inc.
Sanford Burnham Prebys Medical Discovery Institute
Sanford Consortium for Regenerative Medicine
Sangamo BioSciences, Inc.
Scaled Biolabs Inc.
Scripps Health
Scripps Research Institute
Semma Therapeutics
St. Jude Children's Research Hospital
Stanford University
StemCells, Inc.
Technische Universität München
The Scintillon Institute
Tippi C. Mackenzie
TriFoil Imaging, Inc.
Universität Bonn
Universitätsklinikum Erlangen
University Health Network
University Medical Center Goettingen
University of California, Berkeley
University of California, Davis
University of California, Irvine
University of California, Los Angeles
University of California, Merced
University of California, Riverside
University of California, San Diego
University of California, San Francisco
University of California, Santa Barbara
University of California, Santa Cruz
University of Jena
University of Oxford
University of Southern California
Vala Sciences, Inc.
ViaCyte, Inc.
VistaGen Therapeutics, Inc.
Vitalant Research Institute
Western University of Health Sciences
X-Therma Inc.
Zenobia Therapeutics
Zentrum für Integrative Psychiatrie ZIP

Accelerated Development Pathway I
Accelerating Center
Alpha Stem Cell Clinics
Alpha Stem Cell Clinics Network Expansion
ATP3
Basic Biology I
Basic Biology II
Basic Biology III
Basic Biology IV
Basic Biology V
Basic Biology VI
Bridges
Bridges II
Challenge - Genetic Profiling of CIRM’s hiPSC Repository
Clinical Trial Stage Projects
Clinical Trial Stage Projects
Comprehensive Grant
Conference
Conference - Lung Regenerative Medicine Workshop
Conference - Manage a Symposium on Pluripotent Stem Cell Manufacturing
Conference - Manage The 2016 Bridges And SPARK Annual Meetings
Conference - Manage The Bridges Annual Meeting
Conference - Manage The SPARK Annual Meeting
Conference - The 2016 Alpha Stem Cell Clinic Annual Symposium
Conference - The 2017 Alpha Stem Cell Clinic Annual Symposium
Conference - The 2018 Alpha Stem Cell Clinic Annual Symposium
Conference - The 2019 Alpha Stem Cell Clinic Annual Symposium
Conference - The 2020 Alpha Stem Cell Clinic Annual Symposium
Conference II
Conference – The 2020 Grantee Meeting
Coordinating and Information Management Center
Creativity Awards
Cure Sickle Cell Initiative Clinical Trial Stage Projects
Cure Sickle Cell Initiative Late Stage Preclinical Projects
Diagnostic Translational Research Projects
Discovery Research Projects
Discovery Research Projects
Disease Team Planning
Disease Team Research I
Disease Team Therapy Development - Research
Disease Team Therapy Development III
Disease Team Therapy Development IV
Disease Team Therapy Planning I
Early Translational from Disease Team Conversion
Early Translational I
Early Translational II
Early Translational III
Early Translational IV
External Innovation Pilot Program
Genomics Centers of Excellence Awards
Genomics Centers of Excellence Awards (R)
hiPSC Derivation
hPSC Repository
Inception - Discovery Stage Research Projects
iPSC Consortia Award
Late Stage Preclinical Projects
Late Stage Preclinical Projects
Major Facilities
Medical Device Translational Research Projects
New Cell Lines
New Faculty I
New Faculty II
New Faculty Physician Scientist
Patent Assistance Fund Awards
Preclinical Development Awards
Progression Award - Discovery Stage Research Projects
Quest - Discovery Stage Research Projects
Research Leadership
Research Leadership 10
Research Leadership 12
Research Leadership 14
Research Leadership 2
Research Leadership 3
Research Leadership 7
Research Leadership 8
Research Training II
Research Training III
SEED Grant
Shared Labs
SPARK
Stem Cell Therapy Registration Clinical Trials
Strategic Partnership I
Strategic Partnership II
Strategic Partnership III Track A
Strategic Partnership III Track B
Strategic Partnership IV Awards
Supplemental Accelerating Activities
Targeted Clinical Development
Therapeutic Translational Research Projects
Therapeutic Translational Research Projects
Tissue Collection for Disease Modeling
Tool Translational Research Projects
Tools and Technologies I
Tools and Technologies II
Tools and Technologies III
Training Grant I-1
Training Grant I-2
Training Grant I-3
Translating Center
Transplantation Immunology
Visiting Scientist